Stock UMED UNITÉ DE FABRICATION DES MÉDICAMENTS S.A
Add to a list
To use this feature you must be a member
Log inSign up

Financials Unité de Fabrication des Médicaments S.A

Equities

UMED

TN0007720014

Pharmaceuticals

End-of-day quote Tunis
Other stock markets
 18:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
7.17 TND -0.14% Intraday chart for Unité de Fabrication des Médicaments S.A -0.97% -4.14%
2023 Unité de Fabrication des Médicaments S.A Reports Earnings Results for the Half Year Ended June 30, 2023 CI
2023 Unité de Fabrication des Médicaments S.A Reports Earnings Results for the Full Year Ended December 31, 2022 CI

Valuation

Fiscal Period: December 2018 2019 2021 2022 2023 2024 2025
Capitalization 1 265.6 299.8 237.1 227.8 229.4 229.4 -
Enterprise Value (EV) 1 272.9 322.6 255.7 254.5 290.5 296 229.4
P/E ratio 14.5 x 16.9 x 27.2 x - 12.4 x 11.6 x -
Yield 4.16% - 5.48% 6.59% 6.97% 7.67% 8.37%
Capitalization / Revenue 3.05 x 2.8 x 2.81 x 2.36 x 1.71 x 1.63 x 1.55 x
EV / Revenue 3.13 x 3.01 x 3.03 x 2.63 x 2.17 x 2.1 x 1.55 x
EV / EBITDA 8.75 x 8.96 x 10.7 x 10.4 x 7.77 x 7.53 x -
EV / FCF -61.7 x -92.8 x 16.9 x -21.1 x 279 x 32.5 x -
FCF Yield -1.62% -1.08% 5.92% -4.74% 0.36% 3.07% -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 32,000 32,000 32,000 32,000 32,000 32,000 -
Reference price 2 8.300 9.370 7.410 7.120 7.170 7.170 7.170
Announcement Date 19-04-29 20-05-22 22-06-14 23-05-04 - - -
1TND in Million2TND
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2021 2022 2023 2024 2025
Net sales 1 87.09 107.2 84.5 96.62 134 141 148
EBITDA 1 31.18 35.99 23.94 24.51 37.4 39.3 -
EBIT 1 23.89 28.82 13.67 13.41 25.7 27.3 -
Operating Margin 27.44% 26.88% 16.18% 13.88% 19.18% 19.36% -
Earnings before Tax (EBT) - - - - - - -
Net income 1 18.36 17.69 8.703 7.83 16.9 18 19.3
Net margin 21.08% 16.5% 10.3% 8.1% 12.61% 12.77% 13.04%
EPS 2 0.5740 0.5530 0.2720 - 0.5800 0.6200 -
Free Cash Flow 1 -4.425 -3.476 15.13 -12.07 1.04 9.1 -
FCF margin -5.08% -3.24% 17.9% -12.49% 0.78% 6.45% -
FCF Conversion (EBITDA) - - 63.19% - 2.78% 23.16% -
FCF Conversion (Net income) - - 173.83% - 6.15% 50.56% -
Dividend per Share 2 0.3450 - 0.4060 0.4690 0.5000 0.5500 0.6000
Announcement Date 19-04-29 20-05-22 22-06-14 23-05-04 - - -
1TND in Million2TND
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2021 2022 2023 2024 2025
Net Debt 1 7.35 22.7 18.6 26.7 61.1 66.6 -
Net Cash position 1 - - - - - - -
Leverage (Debt/EBITDA) 0.2357 x 0.6317 x 0.7778 x 1.089 x 1.634 x 1.695 x -
Free Cash Flow 1 -4.43 -3.48 15.1 -12.1 1.04 9.1 -
ROE (net income / shareholders' equity) 20.9% 18.3% 8.36% 7.37% 16.1% 16.8% 17.5%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 17.7 18.1 6.29 16.4 20.1 14.8 -
Capex / Sales 20.33% 16.84% 7.44% 16.94% 15% 10.5% -
Announcement Date 19-04-29 20-05-22 22-06-14 23-05-04 - - -
1TND in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Unité de Fabrication des Médicaments S.A

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.17 TND
Average target price
11.9 TND
Spread / Average Target
+65.97%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
UNITÉ DE FABRICATION DES MÉDICAMENTS S.A Stock Unité de Fabrication des Médicaments S.A
-4.14% 73.13M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 325B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
NOVARTIS AG Stock Novartis AG
+3.65% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. UMED Stock
  4. Financials Unité de Fabrication des Médicaments S.A